A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2018
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder; Pervasive child development disorders
- Focus Therapeutic Use
- 25 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 25 Sep 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 25 Sep 2018 Status changed from not yet recruiting to recruiting.